Probiotic interventions in depression have meta-analytic evidence with effect sizes that are modest but consistent — in the SMD 0.3 range for depression scores in randomized trials. The clinical place is as low-cost, low-risk adjunctive intervention in mild-to-moderate depression and as supportive intervention in patients with broader mood and gut symptoms. Strain specificity matters; the evidence is strongest for specific lactobacillus and bifidobacterium species, and product selection requires attention to actual strain content versus generic "probiotic" labeling.
The evidence-supported strains. Lactobacillus rhamnosus, Lactobacillus helveticus, and Bifidobacterium longum have the most consistent depression data. Specific multi-strain products (Probio'Stick, Visbiome, others) have trial data supporting use. The strain-specificity is real — not all lactobacillus species produce equivalent mood effects, and products labeled "probiotic" with unspecified strain content cannot be assumed to have antidepressant effect.
The dose and duration. Effective doses in trials typically use 10^9 to 10^11 CFU daily, taken for 8–12 weeks for meaningful assessment. Higher doses are not necessarily better; the trial range provides guidance. Refrigerated storage typically preserves potency; check product labeling. The treatment duration matters — effects accumulate over weeks, not within days.
The clinical scenarios where probiotics are reasonable. Mild-to-moderate depression as adjunctive intervention. Patients with comorbid GI symptoms (IBS, dysbiosis-related symptoms). Patients with broader interest in microbiome-targeted intervention who want evidence-based product recommendations. Patients seeking augmentation strategies with low side-effect burden. The treatment is not substitute for first-line antidepressant in moderate-severe depression but is reasonable supplement.
The realistic expectations and limitations. Effect sizes are modest — meaningful in some patients, undetectable in others. The literature has meaningful heterogeneity. Product quality varies substantially in the consumer market. The cost ranges from modest to substantial depending on product selection. The treatment is not transformative on its own; it is one component of multi-modal care that, in well-selected patients with adequate adherence and reasonable expectations, produces measurable benefit. The discipline is to recommend specific products with documented strain content and adequate dose, integrate with broader treatment, and assess effect over adequate duration rather than dismissing the intervention or overclaiming its benefit.